– CEO David Bravo emphasizes the critical need for targeted therapies in TNBC, notorious for high recurrence and limited treatment options.
– Following promising animal trials, Pannex aims to commence human clinical trials by early 2026, pending FDA approval.
Pannex Therapeutics, a pioneer in cancer treatment innovation, has achieved a significant breakthrough in the fight against triple-negative breast cancer (TNBC). Their new class of drugs, Panx1 channel blockers, demonstrated in laboratory studies the ability to reduce tumor growth by 80% and metastasis by 90% in animal models. TNBC, characterized by its lack of three common receptors, makes it particularly difficult to treat and is associated with a low five-year survival rate.
The company’s founder and CEO, David Bravo, reported that the drugs, developed to counter the high metastatic potential and recurrence rates of TNBC, have shown no adverse effects in treated animals. These results offer a glimmer of hope for dramatically improving patient outcomes. The drugs work by targeting the Panx1 channels, which are crucial in the cancer’s ability to spread and grow.
Looking ahead, Pannex Therapeutics plans to optimize the top three performing compounds from their studies for further preclinical trials. This step is crucial for obtaining FDA clearance to transition into human clinical trials, aiming to start in 2026. This advancement could significantly impact breast cancer treatment, particularly for TNBC, a form that has historically challenged medical professionals due to its aggressive nature and limited treatment viability.